The U.S. Food and Drug Administration has expanded the approved use of Novartis’ drug Rhapsido, also known as remibrutinib, to treat adults with symptomatic dermographism.

The FDA decision, announced on October 7, 2026, makes remibrutinib the first approved treatment specifically indicated for adults with symptomatic dermographism whose condition is not adequately controlled by H1 antihistamines. Novartis

The approval adds another indication to a medicine that is already approved in the United States for chronic spontaneous urticaria.

What Is Symptomatic Dermographism?

Symptomatic dermographism is a form of chronic inducible urticaria.

People with the condition can develop raised, red and itchy welts after the skin is scratched, rubbed or exposed to pressure.

For some patients, even relatively minor physical contact can trigger symptoms.

The condition can interfere with daily activities because ordinary contact with clothing, scratching or friction may produce uncomfortable skin reactions.

Although antihistamines are commonly used to manage symptoms, some patients continue to experience problems despite treatment.

A New Treatment Option

The FDA’s decision expands the role of remibrutinib for patients whose symptoms remain inadequately controlled with H1 antihistamines.

Novartis describes remibrutinib as an oral, highly selective Bruton tyrosine kinase, or BTK, inhibitor. Novartis

The medicine works through a different biological pathway from conventional antihistamine treatment.

This is significant because patients who do not receive adequate relief from standard treatment may need additional therapeutic options.

Results From the Phase 3 Trial

The approval was supported by results from the Phase 3 RemIND trial.

According to Novartis, approximately twice as many adults receiving Rhapsido achieved complete hive resolution at Week 12 compared with those receiving placebo.

The company also reported that treatment responses were observed as early as Week 2. Novartis

Another report on the clinical findings said that 29.3 percent of patients receiving remibrutinib achieved complete response at Week 12, compared with 14.0 percent in the placebo group. Dermatology Times

These results helped support the regulatory decision.

Why the Approval Matters

Symptomatic dermographism can be difficult to manage for people who continue experiencing symptoms despite standard therapy.

The availability of an FDA-approved treatment specifically for this condition provides physicians with another option when antihistamines are not enough.

The approval is also significant for Novartis because it expands the commercial and clinical role of remibrutinib.

The medicine now has approved uses in both chronic spontaneous urticaria and symptomatic dermographism. AJMC

Oral Treatment Could Improve Convenience

Remibrutinib is an oral treatment.

The availability of an oral option can be convenient for patients compared with therapies that require injections or administration in a clinical setting.

However, convenience is only one part of treatment decisions.

Doctors need to consider a patient’s symptoms, medical history, other medications and individual response when determining the most appropriate therapy.

Patients should therefore discuss treatment choices with qualified healthcare professionals rather than changing medication independently.

Safety Remains an Important Consideration

The FDA approval does not mean the medicine is appropriate for everyone.

Like all prescription medicines, remibrutinib has potential risks and side effects.

Novartis reported that the safety profile observed in symptomatic dermographism was consistent with previous findings in chronic spontaneous urticaria. The company also stated that routine laboratory monitoring is not required under the approved use. Novartis

Patients should still follow prescribing information and medical advice.

A Broader Role for BTK Inhibition

The approval also highlights growing interest in BTK inhibition as a treatment approach for immune-mediated diseases.

BTK is involved in signaling pathways associated with immune-cell activity.

Researchers and pharmaceutical companies have been investigating BTK inhibitors across multiple conditions.

The expansion of remibrutinib’s approved use provides another example of how targeted therapies can be developed for specific immune-related disorders.

What the FDA Decision Means for Patients

For adults living with symptomatic dermographism who continue to experience symptoms despite H1 antihistamines, the FDA approval provides a new prescription treatment option.

The decision does not mean that every patient with skin itching or hives should use remibrutinib.

Symptomatic dermographism can have symptoms that overlap with other skin conditions, so accurate diagnosis remains important.

A healthcare professional can determine whether a patient’s symptoms are consistent with the condition and whether the newly approved treatment is appropriate.

The Future of Chronic Urticaria Treatment

The latest FDA decision reflects continuing progress in the treatment of chronic skin conditions.

For patients whose symptoms remain difficult to control, new targeted medicines can provide additional choices.

Remibrutinib’s expanded approval also demonstrates how clinical research can broaden the use of an existing medicine when evidence supports another medical indication.

As research into immune-mediated skin diseases continues, patients may have access to increasingly targeted therapies designed around the biological mechanisms responsible for their symptoms.

For now, the FDA approval gives adults with symptomatic dermographism another treatment option and marks an important development in the management of chronic inducible urticaria.